Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (1331)	10/1/1999 6:13:00 PM
From: JFitnich	Respond to of 1359

Have to agree that waiting is probably the best strategy. However, I'm already filled to the brim with IPIC (mostly bought in the 2 range). The Bechtle news was disappointing to say the least. I thought (I'm no legal expert) that IPIC would qualify for the settlement status. The worst part of this whole sordid affair was the quote by Barbara Wrubel in the Wall Street Journal, stating that IPIC would not seek bankruptcy protection immediately. She went on to say that IPIC had the dough to continue...but I would have rather have heard an unequivocal NO, absolutely not. Maybe she is just playing her cards close to her vest..I'm not sure. Not the language I wanted to hear from IPIC's top legal gun in any event. I don't think it's an option at this point in time, (or I would have sold by now). Ceraxon results will tell the next chapter in this story (hopefully not the last) and Pagoclone is still looking extremely well positioned in the anxiety market. Here's hoping. JF